Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Liabilities from Discontinued Operations: 2018

  • Ironwood Pharmaceuticals' Liabilities from Discontinued Operations was N/A to $15.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $15.7 million for FY2018, which is N/A change from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Liabilities from Discontinued Operations stood at $15.7 million for Q4 2018, which was up 78,695,100.00% from -$20 recorded in Q1 2010.
  • Over the past 5 years, Ironwood Pharmaceuticals' Liabilities from Discontinued Operations peaked at $15.7 million during Q4 2018, and registered a low of $15.7 million during Q4 2018.
  • Its 1-year average for Liabilities from Discontinued Operations is $15.7 million, with a median of $15.7 million in 2018.